Results 151 to 160 of about 5,260,709 (398)

Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer [PDF]

arXiv, 2020
Serous borderline ovarian tumor (SBOT) and high-grade serous ovarian cancer (HGSOC) are two distinct subtypes of epithelial ovarian tumors, with markedly different biologic background, behavior, prognosis, and treatment. However, the histologic diagnosis of serous ovarian tumors can be subjectively variable and labor-intensive as multiple tumor slides ...
arxiv  

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics

BMC Medical Genomics, 2018
Background The use of next-generation sequencing approaches in clinical diagnostics has led to a tremendous increase in data and a vast number of variants of uncertain significance that require interpretation.
Corinna Ernst, Eric Hahnen, Christoph Engel, Michael Nothnagel, Jonas Weber, Rita K. Schmutzler, Jan Hauke   +6 more
doaj   +1 more source

Machine Learning Methods in the Computational Biology of Cancer [PDF]

, 2014
The objectives of this "perspective" paper are to review some recent advances in sparse feature selection for regression and classification, as well as compressed sensing, and to discuss how these might be used to develop tools to advance personalized cancer therapy.
arxiv   +1 more source

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

American Journal of Human Genetics, 2003
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the average magnitude of these risks is uncertain and may depend on the context.
A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, J. Hopper, N. Loman, Hampus Olsson, O. Johannsson, Å. Borg, B. Pasini, P. Radice, S. Manoukian, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, E. Warner, J. Lubiński, J. Gronwald, B. Górski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjäkoski, O. Kallioniemi, Deborah J. Thompson, Chris Evans, J. Peto, F. Lalloo, D. Evans, D. Easton   +32 more
semanticscholar   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Paraneoplastic thrombocytosis in ovarian cancer [PDF]

, 2012
<p>Background: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear.</p> <p>Methods: We analyzed clinical data on 619 patients with epithelial ...
Akl EA, Alpa M. Nick, Angela F. Drew, Anil K. Sood, Bulent Ozpolat, Chad V. Pecot, Charles N. Landen, Diana Urbauer, Donald Lamkin, Edward H. Ahn, Erin R. King, Frances Balkwill, Francisca Gushiken, Gabriel Lopez-Berestein, Guillermo N. Armaiz-Pena, Hannah Gershenson, Hee Dong Han, Hernan G. Vasquez, Iain A. McNeish, Ibrahim Tekedereli, Jermaine Coward, Justin Bottsford-Miller, Katherine Collins, Koen DeGeest, Koji Matsuo, Mian M.K. Shahzad, Michael T. Deavers, Rajesha Rupaimoole, Rebecca L. Stone, Riess L, Rui Wang, Susan K. Lutgendorf, Vahid Afshar-Kharghan, Virginia K. Bond, Wah Chiu, Wei Hu   +35 more
core   +1 more source

CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability

Molecular Oncology, EarlyView.
Micronuclei, formed during cell division in chromosomal instability settings, rupture and lead to the accumulation of immunogenic double‐stranded RNA in the cytoplasm, activating MAVS‐dependent interferon signaling and innate antitumor immunity.
Aglaia Skolariki, Rose L. Jady‐Clark, Eileen E. Parkes   +2 more
wiley   +1 more source

MicroRNA and ovarian cancer.

Histology and histopathology, 2008
Ovarian cancer remains a leading cause of morbidity and mortality, with little change in survival rates over the past 30 years. Research in the molecular biology underlying the disease demonstrates frequent mutation in the p53/Rb/p16 tumor suppressor pathways and activation of c-myc, K-ras and Akt oncogenic signaling.
Corney, David C., Nikitin, Alexander Yu.
openaire   +4 more sources